Barbara Domayne Hayman
Lid van de Investeringscommissie bij Cambridge Enterprise Ltd.
Profiel
Barbara Domayne Hayman is currently an Investment Committee member at Cambridge Enterprise Ltd.
and the Chief Business Officer at Autifony Therapeutics Ltd.
She holds a doctorate degree from the University of Oxford.
Actieve functies van Barbara Domayne Hayman
| Bedrijven | Functie | Begin |
|---|---|---|
Cambridge Enterprise Ltd.
 Cambridge Enterprise Ltd. Investment ManagersFinance Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge. | Lid van de Investeringscommissie | - |
Autifony Therapeutics Ltd.
 Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Opleiding van Barbara Domayne Hayman
| University of Oxford | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Cambridge Enterprise Ltd.
Cambridge Enterprise Ltd. Investment ManagersFinance Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge. | Finance |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
